| Project item | Indications | Research phase | Cooperation demands |
| NSS-21001 | Cancer cachexia | Preclinical candidate compound identified | License-out or co-development. |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| EP-146 | Human | IL-6[Biotinylated] : IL-6 R apha Inhibitor Screening ELISA Kit | |||
| CEA-C001 | Human | ClinMax™ Human IL-6 ELISA Kit | |||
| CRS-A005 | Human | Human Interleukin-6(IL-6) ELISA Kit | |||
| IL6-C5249 | Cynomolgus | Cynomolgus IL-6 Protein, His Tag (MALS verified) |  |
|
|
| IL6-H82Q9 | Human | Biotinylated Human IL-6 Protein, Avitag™,His Tag |  |
|
|
| IL6-M82Q7 | Mouse | Biotinylated Mouse IL-6 Protein, Avitag™,His Tag |  |
|
|
| IL6-M5245 | Mouse | Mouse IL-6 Protein, His Tag |  |
|
|
| IL6-H8218 | Human | Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling) |  |
|
|
| IL6-H4218 | Human | Human IL-6 Protein, premium grade |  |
|
|
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).
Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | null | 1997-01-01 | Immune System Diseases; Psoriasis | Details | ||
| Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | Mainland China | Multicentric Castleman's Disease (MCD) | Beigene (Beijing) Biotechnology Co Ltd | 2014-04-23 | Monoclonal Gammopathy of Undetermined Significance; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lymphoma, Non-Hodgkin; Lung Neoplasms; Primary Myelofibrosis; Colorectal Neoplasms; Castleman Disease; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Ovarian Neoplasms; Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Polycythemia Vera; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Cytokine Release Syndrome; Head and Neck Neoplasms | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Waldenstrom Macroglobulinemia; Sarcoma; Prostatic Neoplasms; Arachnoiditis; Cholangitis, Sclerosing; Gastrointestinal Hemorrhage; Osteosarcoma; Pancreatitis, Chronic; Retinoblastoma; Sarcoma, Ewing; Lymphoma, Mantle-Cell; Prostatitis; Colitis, Ulcerative; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Erythema Nodosum; Leprosy, Lepromatous; Endometrial Neoplasms; Appendiceal Neoplasms; Pelvic Pain; Angiodysplasia; Glioma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular; Amyotrophic Lateral Sclerosis; Vascular Malformations; Crohn Disease; Precancerous Conditions; Mycobacterium avium-intracellulare Infection; Idiopathic Pulmonary Fibrosis; Leukemia; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Liver Neoplasms; Cough; Telangiectasia, Hereditary Hemorrhagic; Mycobacterium Infections; Rhabdomyosarcoma; Arteriovenous Malformations; Inflammatory Bowel Diseases; Stomatitis, Aphthous; Gastric Antral Vascular Ectasia; Spondylitis, Ankylosing; Myelodysplastic Syndromes; HIV Infections; Coronavirus Dise | Details |
| Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | Mainland China | Multiple Myeloma | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2013-02-08 | Lung Diseases, Interstitial; Neoplasm Metastasis; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Sarcoma, Kaposi; Lymphoma, Non-Hodgkin; Primary Myelofibrosis; Amyloidosis; Sarcoma; Prostatic Neoplasms; Lymphoma, Follicular; Central Nervous System Neoplasms; Bone Marrow Neoplasms; Pulmonary Fibrosis; Multiple Myeloma; Graft vs Host Disease; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Neoplasms; Lymphoma, B-Cell; Medulloblastoma; Solid tumours | Details |
| Lenalidomide | CC-5013; IMiD-3; ENMD-0997; STAR-LLD; CDC-501; IMID-5013; CDC-5013 | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo | EU | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular | Celgene Europe Bv | 2005-12-27 | Lymphoma, T-Cell, Cutaneous; Lymphoma, Follicular; Reflex Sympathetic Dystrophy; Radiculopathy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Histiocytosis, Langerhans-Cell; Prostatic Neoplasms; Demyelinating Diseases; Gliosarcoma; Primary Myelofibrosis; Histiocytic Sarcoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Thrombocytopenia; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Thyroid Neoplasms; Glioma; Leukemia, Monocytic, Acute; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Squamous Cell; Epstein-Barr Virus Infections; Cachexia; Leukemia, Lymphocytic, Chronic, B-Cell; Crohn Disease; Melanoma; Complex Regional Pain Syndromes; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Mental Disorders; Neoplasms; Lymphoma, B-Cell, Marginal Zone; HIV Infections; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Liver Neoplasms; Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia, Erythroblastic, Acute; Hematologic Diseases; Anemia; Paraproteinemias; Pain; Myelodys | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
| Wogonin | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Respiratory Tract Infections; Neoplasms | Details | |
| DMT-210 | DMT-200; DMT-210; DMT-220; SIG-990 | Signum Dermalogix | Details | ||
| FB-704A | FB-704; FB-704A | Fountain Biopharma | Details | ||
| AMG-220 | C-326; AMG-220 | Amgen Inc | Details | ||
| Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Pyoderma Gangrenosum | Details | ||
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Healthy Aging | Details |
| Mycobacterium cell wall-DNA Complex (ProMetic Life Sciences) | EN-3348 | Prometic Life Sciences | Details | ||
| MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
| PF-04236921 | PF-4236921; PF-04236921 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| Ziltivekimab | COR-001 | Phase 3 Clinical | Astrazeneca Pharmaceutical Co Ltd | Cardiovascular Diseases; Renal Insufficiency, Chronic | Details |
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 1 Clinical | Oncoimmune | Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19) | Details |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
| Olokizumab | CDP-6038; Anti-IL6-UCB | Ucb | Details | ||
| Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Post-surgical adhesions; Cicatrix | Details |
| Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Janssen Global Services Llc | Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lupus Erythematosus, Cutaneous; Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
| RO-7200220 | RO-7200220 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Diabetic macular oedema | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Plaque, Atherosclerotic; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Fatigue; Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Stomatitis; Kidney Failure, Chronic | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
